ZEAL Zealand Pharma A/S

+0.43  (+2%)
Previous Close 21.96
Open 22.36
Price To Book 4.34
Market Cap 711,044,423
Shares 31,750,567
Volume 865
Short Ratio
Av. Daily Volume 12,759

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial initiation announced March 6, 2019.
Congenital hyperinsulinism
Phase 3 data released September 18, 2018. Endpoints met.
Severe hypoglycemia in diabetes
Phase 3 trial met primary endpoint - March 2018.
Severe hypoglycemia in diabetes
Phase 3 data due 2020.
Short bowel syndrome
Phase 3 data due September 2019.
Severe hypoglycemia in diabetes - children
Phase 3 trial to commence 2019.
Dasiglucagon dual-hormone pump therapy
Type 1 Diabetes
Phase 3 commencement of enrolment announced May 7, 2019.
Glepaglutide - extension trial
Short bowel syndrome
Phase 1b data due mid-2019.
Obesity / diabetes
Phase 1 initiation of dosing announced June 26, 2019.
Short bowel syndrome (SBS)

Latest News

  1. Total number of shares and voting rights in Zealand Pharma at June 30, 2019
  2. Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome
  3. Zealand Pharma introduces new website to support people living with short bowel syndrome
  4. Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
  5. Zealand Pharma announces amendments to its Articles of Association following the granting of warrants
  6. Zealand Pharma implements a new long-term incentive program and grants new warrants under the employee warrant program
  7. Zealand Pharma presents dasiglucagon pivotal Phase 3 trial data at the 79th Scientific Sessions of the American Diabetes Association (ADA)
  8. Beta Bionics and Zealand Pharma announce superior glycemic control in Phase 2 home-use clinical trial testing the iLet™ bionic pancreas using dasiglucagion
  9. Zealand Pharma to attend Citi European Healthcare Conference
  10. Total number of shares and voting rights in Zealand Pharma as of May 31, 2019
  11. Zealand Pharma to attend Jefferies and Goldman Sachs Global Healthcare Conferences
  12. Beta Bionics and Zealand Pharma initiate home-use trial of the iLet™ bionic pancreas with dasiglucagon for autonomous bihormonal treatment of Type 1 diabetes
  13. Zealand Pharma A/S (ZEAL) Q1 2019 Earnings Call Transcript
  14. Zealand Pharma initiates several Phase 3 studies and grows cash position in the first quarter of 2019
  15. Zealand Pharma achieves primary and all key secondary endpoints in confirmatory Phase 3 trial with dasiglucagon for severe hypoglycemia
  16. Zealand Pharma enrolls first patient in Phase 3 extension study of glepaglutide for treatment for short bowel syndrome
  17. Zealand Pharma hosts conference call on May 16 at 4 pm CET (10 am EST) to present first quarter results for 2019
  18. Zealand Pharma to attend ABG Sundal Collier Small & Mid Cap Seminar